People on the Move Management Changes at Dupont, Johnson & Johnson, Lyondell Basell & Co.

Several of the major international process industry groups will soon have new management personnel. In addition to Dupont, Lyondell Basell and Lonza, Johnson & Johnson, Pfizer and Jubilant Therapeutics have also announced changes at the top levels. PROCESS worldwide summarizes the latest announcements for you.

Würzburg/Germany — Biopharma company Jubilant Therapeutics is strengthening its board of directors with the addition of Dr. Leila Alland and has announced the appointment of Dr. Jeremy Barton as strategic advisor and interim CMO. Dr. Alland currently serves as Chief Medical Officer at PMV Pharmaceuticals, where she is responsible for leading the clinical phase of the company's precision cancer therapies. Previously, she was chief medical officer at Affimed and Tarveda Therapeutics and held leadership positions at Astra Zeneca, Bristol-Myers Squibb, Novartis and Schering-Plough. Alland completed her fellowship in pediatric hematology-oncology at New York Hospital and Memorial Sloan-Kettering Cancer Center and was an assistant professor of pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and conducted basic research in cancer while caring for children with cancer and blood disorders.

Dr. Barton brings to Jubilant Therapeutics over 29 years of experience in all phases of cancer drug development, working for major pharmaceutical companies in Switzerland, the UK and the US. He currently serves as a consultant to biotech companies in the strategic development of cancer drugs. Previously, Barton served as chief medical officer at Biogen Idec, Effector Therapeutics and Mirati Therapeutics. He was head of early oncology development at Pfizer, where he oversaw the transition of all oncology compounds from research to IND and then to proof-of-concept studies. Barton is a consultant in internal medicine and clinical oncology, a member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology), and a member of the Faculty of Pharmaceutical Medicine. He received his master's degree in physiology from Oxford University and his doctorate from University College Hospital Medical School in London.

Gallery

Dupont Appoints New President for Water & Protection

Dupont announced that Leland Weaver has been named president of its Water & Protection business, effective Sept. 1, 2021. Weaver will report directly to Ed Breen, executive chairman and CEO.

Weaver currently serves as vice president, investor relations, where he has played a leading role in communicating with the investment community about the company's growth strategy and transformation into a leading multinational company. He joined Dupont in 2003 as an engineer and has since held leadership positions of increasing responsibility in manufacturing, sales, marketing and finance across multiple business units. Weaver earned a Bachelor of Science degree in chemical engineering from the University of Alabama and an MBA from the Wharton School of the University of Pennsylvania.

Pharmaceutical Giant Johnson & Johnson Announces Management Change

New Brunswick (dpa) - U.S. pharmaceutical company Johnson & Johnson is preparing a change at the top of its board. Longtime chairman Alex Gorsky will vacate the post on January 3, 2022, and become executive chairman of the company's board of directors, Johnson & Johnson announced.

Joaquin Duato, who like Gorsky has been with the company for more than three decades and has been a top executive for some time, has been named his successor, the company stated. Duato is currently vice chairman of Johnson & Johnson's executive committee. He is also expected to join the board of directors, which is superior to the executive committee.

Gorsky, who has been at the helm of the company since 2012, said in the release that he wanted to step down as CEO for “family health reasons”. He also said it was the right time for a change due to the company's good condition. Investors reacted calmly, and the share hardly moved after trading hours.

PROCESS Insights 2020-06
Economic Evaluation of Petrochemical Projects after Corona

In the post Corona time and due to the oil price crash, the economics of large petrochemical projects has changed significantly, which made it necessary to reevaluate the planned projects. When evaluating the economics of a large project such as a cracker-based polymer complex, many factors have to be considered and have to be tested in different scenarios.

In this paper, our expert will provide you with a simple model and method for the economics evaluation of petrochemical projects and will explain possible scenarios.

Buy now!

Lyondell Basell Announces Resignation of Chief Executive Officer

The Chief Executive Officer of Lyondell Basell, Bhavesh V. (Bob) Patel, will retire from the company on December 31, 2021. Patel intends to continue to lead the company until that date and ensure a smooth and orderly transition for his successor. Upon his retirement, he will also step down from the company's Board of Directors. The board has formed a committee to oversee the search for a new CEO and consider both internal and external candidates.

Patel joined the company in March 2010 and was appointed CEO in January 2015. Since then, the Group has grown significantly through a series of strategic global investments, including the acquisition of A.Schulman, the construction of world-scale manufacturing facilities on the U.S. Gulf Coast, and the establishment of new or expanded joint ventures in the United States, China, Korea and Thailand.

China's Pharmaceutical Equipment Market 2020: Current Status, Trends, and Recommended Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

Pfizer Names New Chief Business Innovation Officer

Pharmaceutical company Pfizer has recruited Aamir Malik as executive vice president and chief business innovation officer. Malik will join the company's executive leadership team and report to chairman and chief executive officer, Albert Bourla. Malik joins Pfizer from McKinsey & Company, where he was most recently managing partner responsible for the company's U.S. operations. Prior to that, he led the firm's Global Pharmaceuticals & Medical Products business.

Malik succeeds John Young, executive vice president and chief business officer, who recently announced his intention to retire after a 34-year career with Pfizer. Malik will assume his role on August 30, 2021, and is expected to work with John Young to ensure a seamless transition.

At Pfizer, Malik will oversee the company's strategy, business development, portfolio management, pipeline prioritization and new venture creation, as well as driving innovative access partnerships with payers and governments around the world.

Malik earned a Bachelor of Science degree in finance from Indiana University and currently serves on the Dean's Council of the University's Kelley School of Business. He is an active advocate for improving the lives of people with food allergies and has lived and worked around the world, including the U.S., Europe, Asia, Latin America and Africa.

Gallery

Philippe Deecke to Become New Chief Financial Officer of Lonza Group

Lonza's Board of Directors announced that Philippe Deecke has been appointed as the Group's new Chief Financial Officer (CFO). The appointment will take effect on December 1, 2021. Deecke will succeed Rodolfo J. Savitzky as a member of the Executive Committee.

Deecke joins Lonza from Novartis, where he held a number of senior finance positions. He has been with Novartis for more than 16 years and most recently served as Global CFO for Novartis Oncology. In this role, he was responsible for the long-term financial performance, planning, controlling, reporting and compliance of a major Novartis business unit.

Prior to his most recent role at Novartis Oncology, Deecke served as Global CFO for Sandoz, a division of Novartis specializing in generics and biosimilars, from 2017 to 2021. In this role, he supported margin improvement across the business, including the manufacturing network, and enabled business growth with a strategic approach to business development and licensing (BD&L) and M&A activities. Previously, Deecke served in various roles at Novartis, including CFO of Alcon Emea, a former division of Novartis (from 2015 to 2017), and Head of Management Reporting and Corporate Planning for the Novartis Group (from 2012 to 2015).

Prior to joining Novartis, Deecke worked for more than six years at McKinsey as an associate principal and member of the European Pharma and Medical Products Practice. In this role, he specialized in developing growth strategies for a broad range of pharmaceutical industry clients.

Deecke holds an MBA from the Johnson School at Cornell University (US), a Master's degree in Industrial Management and Manufacturing from ETH Zurich (CH) and a Bachelor's degree in Computer Science from ETH Zurich (CH).

(ID:47619432)